7 Top Stocks Under $10: June 2024 Edition

InvestorPlace06-24

Meet Louis Navellier Summit Therapeutics (SMMT): The company has two Phase 3 trials underway with its lead candidate, ivonescimab, which would be used as an investigational bispecific antibody ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2445024553?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-24 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2445024553","market":"us","top_or_hot":-1,"title":"7 Top Stocks Under $10: June 2024 Edition","media":"InvestorPlace","content":"<div>\n<p>Meet Louis Navellier\t\t\n\n\n\n\n\nSummit Therapeutics (SMMT): The company has two Phase 3 trials underway with its lead candidate, ivonescimab, which would be used as an investigational bispecific antibody ...</p>\n\n<a href=\"https://investorplace.com/market360/2024/06/7-top-stocks-under-10-june-2024-edition/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Top Stocks Under $10: June 2024 Edition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Top Stocks Under $10: June 2024 Edition\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-24 18:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/market360/2024/06/7-top-stocks-under-10-june-2024-edition/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Meet Louis Navellier\t\t\n\n\n\n\n\nSummit Therapeutics (SMMT): The company has two Phase 3 trials underway with its lead candidate, ivonescimab, which would be used as an investigational bispecific antibody ...</p>\n\n<a href=\"https://investorplace.com/market360/2024/06/7-top-stocks-under-10-june-2024-edition/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TQQQ","symbol_name":"纳指三倍做多ETF","start_time":0,"source_url":"https://investorplace.com/market360/2024/06/7-top-stocks-under-10-june-2024-edition/","article_id":"2445024553","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2445024553","pubTimestamp":1719225300,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"While blue chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification.","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TQQQ":"纳指三倍做多ETF","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","PSQ":"纳指反向ETF","ANNX":"Annexon, Inc.","QLD":"纳指两倍做多ETF","SMMT":"Summit Therapeutics PLC","BK4548":"巴美列捷福持仓","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","QQQ":"纳指100ETF","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","AMZN":"亚马逊","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","BK4583":"猴痘概念","SQQQ":"纳指三倍做空ETF","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SMR":"NuScale Power","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","BK4534":"瑞士信贷持仓","EBS":"Emergent Biosolutions","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","BK4007":"制药","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","HSHP":"Himalaya Shipping Ltd.","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","BK4557":"大麻股","ACB":"奥罗拉大麻公司","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","BK4535":"淡马锡持仓","LU0082616367.USD":"摩根大通美国科技A（dist）","BK4220":"综合零售","BK4113":"食品零售","BK4559":"巴菲特持仓","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK4538":"云计算",".IXIC":"NASDAQ Composite","REBN":"Reborn Coffee, Inc.","LU0061474960.USD":"天利环球焦点基金AU Acc","QID":"纳指两倍做空ETF","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC"},"translate_title":"7只10美元以下的热门股票：2024年6月版","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACB":1,"EBS":1,"HSHP":1,"REBN":1,"SMMT":1,"SMR":1,"ANNX":1,".IXIC":0.87,"AMZN":0.7,"TQQQ":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Meet Louis Navellier\t\t\n\n\n\n\n\nSummit Therapeutics (SMMT): The company has two Phase 3 trials underway with its lead candidate, ivonescimab, which would be used as an investigational bispecific antibody to treat non-small cell lung cancer.\nAnnexon (ANNX): Its pipeline includes a potential treatment for Guillain-Barre syndrome, a rare disorder in which the body’s immune system.\nAurora Cannabis (ACB): Aurora is seeing big increases in revenue from medicinal cannabis.\nRead on to find more great top-rated stocks for less than $10!\n\n\n\n\n\n \n\nSource: Shutterstock\n\n\n\nWhile blue chip stocks are always a good investment portfolio idea, I suggest some smart diversification. And one of the best ways that I know to diversify is to buy highly rated stocks under $10.\nStocks under $10 may not sound interesting, but these names can be a strategic move for anyone wanting to diversify and improve their portfolios. \nWhile cautious investors will associate lower-priced stocks with higher risk, the Portfolio Grader can help you find some outstanding choices to round out a portfolio.\nIt’s important to remember that stocks under $10, when included in a portfolio of blue-chip equities, can expose you to smaller companies with high growth potential. And diversification is important because if you have a falling segment, your gains from other sectors can help you mitigate your losses.\nThe Portfolio Grader can help you find stocks that are priced low, not because they are struggling but because they are an excellent opportunity. Stocks under $10 could be priced that way because of restructuring or because the company is in an emerging industry.\nBy evaluating stocks based on momentum, analyst sentiment, revenue growth and earnings performance, you have a better chance of choosing quality stocks under $10 for your portfolio. These seven names are a good place to start.\nSummit Therapeutics (SMMT)\nSource: ShutterstockSummit Therapeutics (NASDAQ:SMMT) is a biopharmaceutical company that works on the discovery, development and commercialization of therapies for unmet medical needs.\nThe company currently has two Phase 3 trials underway with its lead candidate, ivonescimab, an investigational bispecific antibody to treat non-small cell lung cancer.\nThe company recently raised $200 million from an institutional investor for 22.2 million shares of SMMT stock. It plans to use the money to advance the development of ivonescimab, with the goal of completing Phase 3 trials and submitting the treatment to regulators for approval.\nThat money will be added to the $157 million the company had on hand at the end of the first quarter, in which it spent $46.2 million on operating expenses. The company doesn’t have an income stream yet, so it posted a loss of $34 million, or 5 cents per share, for the first quarter.\nSMMT stock is up 196% in 2024 and gets a “B” rating in the Portfolio Grader.\nAnnexon (ANNX)\nSource: ShutterstockAnnexon (NASDAQ:ANNX) is a California-based bioscience company developing treatments for autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain, and eye.\nIts impressive pipeline includes a potential treatment for Guillain-Barre syndrome, a rare disorder in which the body’s immune system is expected to report Phase 3 trials in the fourth quarter.\nIt also has Phase 2 trials for potential treatments for geographic atrophy, Huntington’s disease and amyotrophic lateral sclerosis, otherwise known as ALS.\nEarnings for the first quarter included $21 million in research and development expenses and $7.6 million in administrative costs. The company has cash and cash equivalents of $264.9 million and expects to have enough money currently to fund operations into mid-2026.\nANNX stock is up 14% this year and gets a “B” rating in the Portfolio Grader.\nAurora Cannabis (ACB)\nSource: ShutterstockAurora Cannabis (NASDAQ:ACB) is a Canadian cannabis company that is considered a leading producer of medical cannabis in Canada.\nThe company has a variety of medical-use and adult recreational products, including flower products, vapes, edibles, concentrates and more.\nCannabis stocks were a hot commodity in 2020 when there was an expectation that the Biden administration and a Democratic-controlled Congress would push through federal legalization of marijuana rather than leaving it to the states. \nHowever, the Covid-19 pandemic and inflationary issues derailed those plans, and federal recreational use is still a pipe dream for Aurora investors.\nHowever, the Justice Department is recommending that cannabis be reclassified from a Schedule 1 to a Schedule 3 drug, which would give marijuana stocks a boost.\nAurora’s financial results for the fourth quarter of fiscal 2024 (ending March 31) included $67.4 million in revenue, up 5% from the previous year. Medicinal cannabis made up a large part of that increase, as it was up 20% from last year, while adult recreational use was down 29%.\nI expect the numbers for adult recreational cannabis to improve. ACB stock is up 15% this year and gets a “B” rating in the Portfolio Grader.\nHimalaya Shipping (HSHP)\nSource: ImagineStock / Shutterstock.comBased in Bermuda, Himalaya Shipping (NYSE:HSHP) is a new entrant into the shipping business. It just accepted delivery of its 12th dual-fueled dry bulk vessel from a Chinese shipyard, with each ship capable of transporting 210,000 in dead weight tonnage.\nAs new ships, the fleet of next-generation cargo ships can use liquefied natural gas for propulsion, reducing per-ton emissions by 60%. The company also started paying a monthly dividend in January, and plans to continue the practice that will be popular for income investors.\nEarnings for the first quarter of 2024 included revenue of $23.6 million and net income of $2.5 million. Now that the fleet is fully operational, Himalaya Shipping should see those numbers improve.\nHSHP stock is up 27% in 2024 and gets an “A” rating in the Portfolio Grader.\nEmergent BioSolutions (EBS)\nSource: T. Schneider / Shutterstock.comEmergent BioSolutions (NYSE:EBS) is a biopharmaceutical company headquartered in Maryland. The company develops vaccines and antibody therapies for infectious diseases and to treat opioid overdoses.\nThe company has countermeasures to combat some of the most critical public health threats in the world, including smallpox, anthrax and botulism. It also makes a reactive skin decontamination lotion kit among other products.\nMeanwhile, its pipeline includes potential treatments for Lassa fever, Ebola, and influenza.\nThe company is undoubtedly doing important work, and it’s being well rewarded. Revenues in the first quarter were $300.4 million, up from $164.3 million in the same quarter a year ago. The company also posted a profit of $9 million after posting a loss of $186.2 million in the first quarter of 2023.\n EBS stock is on a roll this year, up 169% so far. It gets a “B” rating in the Portfolio Grader.\nReborn Coffee (REBN)\nSource: Evgeny Karandaev/ShutterStock.comReborn Coffee (NASDAQ:REBN) is a specialty coffee maker. Coffee is one of the most popular drinks in the U.S., with an estimated 73% of American consumers acknowledging being a coffee drinker. \nIt seems there’s coffee for every pallet, including high-priced coffeehouse drinks to at-home drip coffee makers that give you a basic cup of joe.\nReborn Coffee is has only 14 locations, mostly in California. But it also offers a subscription service on its website, and makes whole-bean products, pour-over packs and cold brew packs.\nIt doesn’t expect to stay small for long. Reborn announced an expansion into China and Southeast Asia and plans to open a location in Abu Dhabi. It also has serious e-commerce plans by making its products available on Amazon (NASDAQ:AMZN).\nEarnings for the fourth quarter of 2023 included revenue of $1.8 million, up 109% from the same quarter a year ago. Full-year revenue was $6 million versus $3.2 million in 2022.\nREBN stock is up 48% this year and gets a “B” rating in the Portfolio Grader.\nNuScale Power (SMR)\nSource: T. Schneider / Shutterstock.comNuScale Power (NYSE:SMR) is an Oregon company that makes small modular light water nuclear reactors that are expected to help companies phase out coal-powered plants.\nThe company also is seeking approval for a proposal in Romania that would be the first European project to use small modular light nuclear reactor technology. The effort has $4 billion in commitments for U.S. financial institutions, and the company is hoping to get approval in 2025.\nSuch a deal would be a massive win for NuScale and its investors.\nSMR stock, which has reactors that can provide power in nuclear plants, is under $10 now but probably won’t be for long. It is currently up 190% in 2024 and gets a “B” rating in the Portfolio Grader.\nOn the date of publication, neither Louis Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.\nHealthcare, Biotech, Energy, Renewable Energy, Consumer Discretionary, Retail, Restaurant, Industrial, Shipping\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\n Louis Navellier\nEditor, Market 360\n\n\nMeet Louis Navellier\nLouis Navellier is one of Wall Street’s renowned growth investors. Providing investment advice to tens of thousands of investors for more than three decades, he has earned a reputation as a savvy stock picker and unrivaled portfolio manager.\n\n\n\t\t\t\tLearn more about Louis\t\t\t\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/market360/2024/06/7-top-stocks-under-10-june-2024-edition/.\n©2024 InvestorPlace Media, LLC","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2445024553"}